Clinical Trial Update: Immunomodulation With Eltrombopag in ITP [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating immunomodulation with eltrombopag in primary immune thrombocytopenia has completed. The study was sponsored by University Ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: University Children's Hospital Basel | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 2 | Status: COMPLETED